NVDA vs PEGA

NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.

PEGA demonstrates exceptional financial health with a Piotroski F-Score of 8/9 and a very low Debt/Equity ratio of 0.10. While the stock trades at a significant discount to its growth-based intrinsic value ($62.83) and analyst targets ($59.36), it is severely hindered by stagnant revenue growth of only 2.70% and an alarmingly high PEG ratio of 15.20. The divergence between strong internal efficiency (ROE 57.32%) and poor top-line growth, coupled with bearish insider selling and a 0/100 technical trend, suggests a period of consolidation or transition.